A virus previously confined to Africa and Asia has made its first known appearance in Europe, and researchers say it is raising new questions even after years of studying closely related pathogens.
Shamonda virus (SHAV) was detected in European livestock for the first time during the summer of 2026, according to Wageningen University & Research (WUR) in the Netherlands. Since then, the virus has spread rapidly across the continent, and scientists have identified two distinct genetic variants, which they have named EU-1 and EU-2.
SHAV primarily infects ruminants such as cattle, sheep and goats, and is transmitted by biting midges of the Culicoides genus. The virus was first isolated from cattle in Nigeria in 1965, and has since been found in various regions of Africa and Asia. Its arrival in Europe marks a significant geographical expansion.
In cattle, infection can cause fever, diarrhoea, reduced milk production and reproductive disorders, including abortion and congenital abnormalities in offspring. WUR reported that neurological symptoms have also been observed in horses.
Perhaps the most concerning development came in October 2026, when the virus attracted international attention following the first reported human infection. According to WUR, a patient in France with severe underlying health conditions died from encephalitis linked to SHAV. For many years, the virus was considered exclusively an animal pathogen.
"These findings are not entirely unexpected," WUR researchers noted, "but they highlight the potential for animal viruses to cross species barriers and pose new risks to public health."
SHAV belongs to the orthobunyaviruses within the Simbu serogroup. It is closely related to the Schmallenberg virus, which caused widespread outbreaks in Europe in 2011, and the Shuni virus, which occurs in southern Africa and has recently been detected in Israel. Wageningen Bioveterinary Research (WBVR) has extensive experience studying both of those viruses, providing what the institution describes as a strong scientific foundation for investigating SHAV.
Despite this background, the precise epidemiology, transmission dynamics and clinical impact of SHAV are not yet fully understood. WUR emphasised that further surveillance and research remain essential.
Researchers are currently investigating the genetic differences between the EU-1 and EU-2 variants, the role of biting midges in transmission, and the consequences of infection for animals and potentially humans. They are also studying the immune response to the virus, including the role of antibodies, and using advanced cell models to examine SHAV's ability to infect different host species.
There are currently no vaccines or specific treatments available for SHAV. However, WUR said knowledge gained from research into related viruses provides a solid basis for rapidly assessing the characteristics of SHAV, its transmission dynamics and the potential risks.
In a separate development, SHAV RNA was detected in buffalo milk in Italy, suggesting a possible alternative source of infection. WUR noted that this finding, while not entirely unexpected, adds another dimension to the risk assessment.
For livestock farmers, the economic consequences could be significant. Although much remains unknown about the virus, the reported effects on milk production, fertility and animal health could have financial implications. WUR stressed that early detection, surveillance and reporting of suspected clinical signs are important to better understand and manage the impact.
WUR's bioveterinary research team includes dr. Melle Holwerda, Paul Wichgers Schreur, prof.dr. Barry Rockx and ing. Renate van der Honing-Hakze, who are leading the investigation into the virus's spread and risks.